- (Shionogi) A phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (S-005151) compared with placebo in adult participants with acute ischemic stroke who are not eligible for tissue plasminogen activator or thrombectomy
Clinical Trial
(Shionogi) A phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (S-005151) compared with placebo in adult participants with acute ischemic stroke who are not eligible for tissue plasminogen activator or thrombectomy
This study will compare the effectiveness and safety of redasemtide vs placebo in stroke patients who aren't eligible for tPA or thrombectomy. Redasemtide will be given for five days while the patient is in the hospital. After discharge, the patient will return to the clinic for three visits over six months.
Eligibility Criteria
- Aged 18 years or older diagnosed with ischemic stroke Can start study medication within 25 hours of stroke onset Not eligible for fPA or thrombectomy
RESEARCH. INNOVATION. DISCOVERY.